Cerebrospinal fluid cytokines and metalloproteinases in cerebral amyloid angiopathy‐related inflammation

2020 ◽  
Author(s):  
Kenji Sakai ◽  
Moeko Noguchi‐Shinohara ◽  
Tokuhei Ikeda ◽  
Tsuyoshi Hamaguchi ◽  
Kenjiro Ono ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Cerebral Amyloid Angiopathy ◽  
Amyloid Angiopathy ◽  
Cerebral Amyloid

scholarly journals Cerebrospinal fluid biomarkers and apolipoprotein E genotype in cerebral amyloid angiopathy. A narrative review

2021 ◽  
Vol 2 ◽  
pp. 100010
Author(s):  
Aikaterini Theodorou ◽  
Ioanna Tsantzali ◽  
Elisabeth Kapaki ◽  
Vasilios C. Constantinides ◽  
Konstantinos Voumvourakis ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Apolipoprotein E ◽  
Cerebral Amyloid Angiopathy ◽  
Narrative Review ◽  
Amyloid Angiopathy ◽  
Cerebrospinal Fluid Biomarkers ◽  
Cerebral Amyloid ◽  
Apolipoprotein E Genotype

Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation

2015 ◽  
Vol 50 (1) ◽  
pp. 1-7 ◽  
Author(s):  
María Carmona-Iragui ◽  
Ana Fernández-Arcos ◽  
Daniel Alcolea ◽  
Fabrizio Piazza ◽  
Estrella Morenas-Rodriguez ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Cerebral Amyloid Angiopathy ◽  
Amyloid Β ◽  
Amyloid Angiopathy ◽  
Amyloid Pet ◽  
Cerebral Amyloid

scholarly journals Patterns of Cerebrospinal Fluid Biomarkers and Amyloid Positron Emission Tomography in a Patient with Cerebral Amyloid Angiopathy-Related Inflammation

2021 ◽  
Vol 39 (3) ◽  
pp. 172-176
Author(s):  
Ji-Yon Kim ◽  
Sungyang Jo ◽  
Yun Jik Park ◽  
Hee Jae Jung ◽  
Yong Seo Koo ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Cerebral Amyloid Angiopathy ◽  
Behavioral Change ◽  
Inflammatory Lesion ◽  
Amyloid Angiopathy ◽  
Laboratory Findings ◽  
Amyloid Positron Emission Tomography ◽  
Positron Emission ◽  
Cerebrospinal Fluid Biomarkers ◽  
Cerebral Amyloid

Cerebral amyloid angiopathy-related inflammation (CAA-RI) is a distinct subset of cerebral amyloid angiopathy characterized by the auto-inflammatory response to amyloid-laden small arteries of cerebral cortex and leptomeninges. Clinical features include cognitive-behavioral change, headache, focal neurologic deficits and seizure. Because anti-inflammatory treatments can rapidly relieve neurologic symptoms, early diagnosis is critical. Herein, we report a CAA-RI case with distinct laboratory findings of a decreased cerebrospinal fluid amyloid beta 1-42 level and relatively reduced florbetaben uptake in the focal inflammatory lesion during the acute phase of CAA-RI.

scholarly journals Reduced Levels of Cerebrospinal Fluid/Plasma Aβ40 as an Early Biomarker for Cerebral Amyloid Angiopathy in RTg-DI Rats

2020 ◽  
Vol 21 (1) ◽  
pp. 303 ◽  
Author(s):  
Xiaoyue Zhu ◽  
Feng Xu ◽  
Michael D. Hoos ◽  
Hedok Lee ◽  
Helene Benveniste ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Cerebral Amyloid Angiopathy ◽  
Late Stage ◽  
Cerebral Microbleeds ◽  
Amyloid Angiopathy ◽  
Amyloid Β Protein ◽  
Stage Disease ◽  
Late Stage Disease ◽  
Cerebral Amyloid ◽  
Cerebral Vascular

The accumulation of fibrillar amyloid β-protein (Aβ) in blood vessels of the brain, the condition known as cerebral amyloid angiopathy (CAA), is a common small vessel disease that promotes cognitive impairment and is strongly associated with Alzheimer’s disease. Presently, the clinical diagnosis of this condition relies on neuroimaging markers largely associated with cerebral macro/microbleeds. However, these are markers of late-stage disease detected after extensive cerebral vascular amyloid accumulation has become chronic. Recently, we generated a novel transgenic rat model of CAA (rTg-DI) that recapitulates multiple aspects of human CAA disease with the progressive accumulation of cerebral vascular amyloid, largely composed of Aβ40, and the consistent emergence of subsequent microbleeds. Here, we investigated the levels of Aβ40 in the cerebrospinal fluid (CSF) and plasma of rTg-DI rats as CAA progressed from inception to late stage disease. The levels of Aβ40 in CSF and plasma precipitously dropped at the early onset of CAA accumulation at three months of age and continued to decrease with the progression of disease. Notably, the reduction in CSF/plasma Aβ40 levels preceded the emergence of cerebral microbleeds, which first occurred at about six months of age, as detected by in vivo magnetic resonance imaging and histological staining of brain tissue. These findings support the concept that reduced CSF/plasma levels of Aβ40 could serve as a biomarker for early stage CAA disease prior to the onset of cerebral microbleeds for future therapeutic intervention.

scholarly journals Metabolomics biomarker discovery in cerebrospinal fluid for cerebral amyloid angiopathy

2020 ◽  
Vol 16 (S4) ◽  
Author(s):  
Emma van den Berg ◽  
H. Bea Kuiperij ◽  
William E. Van Nostrand ◽  
Tessa M.A. Peters ◽  
Karlien L.M. Coene ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Cerebral Amyloid Angiopathy ◽  
Biomarker Discovery ◽  
Amyloid Angiopathy ◽  
Cerebral Amyloid
Sign in / Sign up

Export Citation Format

Share Document